Trientine is unavailable in my country — can I import it, and is zinc alone an acceptable substitute?

Trientine is not available in every country, and in countries where it is licensed, its cost has historically been prohibitive for many patients. If you are facing a supply gap — whether because your local pharmacy cannot source it, it is not registered in your country, or the price makes it inaccessible — this article addresses two practical questions: what legal options exist to obtain trientine, and whether zinc alone can fill the gap if trientine cannot be obtained.

The honest short answer: zinc-only is not an acceptable substitute for most patients with active disease, but it may be a viable bridge or maintenance strategy in carefully selected situations — and that decision must be made with your specialist, not independently.

Why trientine access is uneven globally

Trientine was developed and patented in the United States and UK in the 1960s–70s as an alternative to penicillamine for patients who could not tolerate penicillamine’s side effects.¹ For decades it was only licensed in a small number of countries, making it essentially unavailable without importation in much of Asia, Latin America, Africa, and parts of Eastern Europe.

That landscape has shifted somewhat since the approval of trientine tetrahydrochloride (TETA-4HCl) in the European Union in 2022 and the United States, and with the increasing availability of generic trientine dihydrochloride (TETA-2HCl) formulations in some markets.² But “available somewhere” does not mean available at your pharmacy. If your country’s regulatory body has not registered the product, obtaining it requires one of the routes below.

Legal pathways to obtain trientine

1. Named-patient or compassionate-use importation

Most countries with a functioning medicines regulatory system have a mechanism for importing unlicensed medicines for individual patients — variously called “named-patient supply,” “special access,” “compassionate use,” or “Section 56” (UK terminology). The process typically requires:

• A prescription from a licensed specialist
• An application to the national medicines regulatory authority (or sometimes just to customs/pharmacy)
• Importing from a licensed manufacturer or distributor in a country where it is approved

Your Wilson disease specialist or a hospital pharmacist familiar with rare disease importation can initiate this process. In many countries it is bureaucratically straightforward once the prescription is in place, though lead times can be weeks to months. Some hospital pharmacies in major centers maintain established importation channels for Wilson disease medications.

2. Expanded access or trial enrollment

If you live near a center participating in Wilson disease research, compassionate-use or expanded-access programs associated with ongoing trials may provide access to approved or investigational chelation agents. Ask your specialist whether any such programs are open at your institution or regionally.

3. Manufacturer patient assistance programs

Manufacturers of brand-name trientine (including those who hold EU and US approvals) sometimes operate patient assistance programs or international named-patient supply programs for patients in low- and middle-income countries. These programs are inconsistent and not universally available, but they are worth inquiring about directly with the manufacturer. Your hepatologist or a patient advocacy organization (such as the Wilson Disease Association in North America or WDSUK) can assist with making contact.

4. Penicillamine as an alternative chelator

If trientine is genuinely unobtainable, penicillamine (d-penicillamine, DPA) remains the alternative first-line chelator in most global guidelines and is registered in many more countries than trientine.³ Its side effect profile is more complex — including hypersensitivity reactions, renal toxicity, bone marrow suppression, and worsening of neurological symptoms in some patients — but it is an effective copper chelator when tolerated. If your choice is between penicillamine (available) and nothing (trientine unavailable), penicillamine is generally the right clinical decision.

Do not make this substitution without your specialist’s involvement. The dosing and monitoring protocols for penicillamine differ from trientine, and hypersensitivity reactions can occur early.

Is zinc alone acceptable as a substitute?

This is the more complicated question, and the answer depends on what “substitute” means in your specific situation.

Zinc as primary therapy for symptomatic or active liver disease: generally not acceptable

Multiple studies have established that zinc monotherapy is less effective than chelation (penicillamine or trientine) for achieving adequate copper decoppering in patients with significant active liver disease.⁴ In a landmark study by Weiss and colleagues, patients with active hepatic Wilson disease on zinc monotherapy had significantly worse outcomes than those on chelation agents — including progression to liver failure in some cases where zinc alone was being used for hepatic decompensation.⁵

The mechanism explains this: zinc works by blocking intestinal copper absorption, not by actively removing already-accumulated copper from the liver and brain. In a patient with a large existing copper burden causing active hepatocyte injury, zinc simply cannot remove copper fast enough to prevent ongoing damage. The liver needs the direct chelation and excretion that penicillamine or trientine provide.

A published case series further documented patients who deteriorated neurologically while on zinc monotherapy, with improvement only after a chelator was added.⁶

Zinc alone for symptomatic or newly diagnosed disease with significant liver involvement should not be used unless chelation is genuinely impossible and the alternative is no treatment at all.

Zinc as maintenance therapy after adequate decoppering: often acceptable

The picture is entirely different for maintenance. Current guidelines allow zinc monotherapy for patients who have already achieved adequate copper decoppering on chelation and are clinically stable — particularly those who are presymptomatic, have neurological disease only (with stable or normal liver function), or are in long-term maintenance after years of good response.³⁷

In this context, zinc is effective at preventing re-accumulation and has a favorable safety profile. Studies of zinc acetate and zinc sulfate for maintenance have shown adequate copper control in stable patients.⁷ Switching from a chelator to zinc maintenance is a well-recognized clinical strategy for some patients, particularly during pregnancy where chelation doses are reduced.

The bridge scenario

If you are currently well-controlled on trientine and face a temporary supply interruption — not a permanent one — zinc may be an appropriate bridge for a limited period while trientine supply is secured, particularly if your disease is hepatically stable and your most recent copper markers were reassuring. This requires:

• Your specialist’s explicit agreement
• Close monitoring of liver function tests and symptoms during the gap
• A concrete plan to resume chelation

This is not a decision to make unilaterally. The risk of undertreatment — particularly in neurological Wilson disease — is real. Copper can re-accumulate faster than expected when chelation is interrupted, and neurological deterioration can be rapid and difficult to reverse.

What to tell your specialist

Bring the access problem to your specialist explicitly and early — not after you have already run out. The conversation should cover:

1. Which named-patient importation channels exist in your country
2. Whether penicillamine is an acceptable alternative given your specific disease history
3. Whether, if neither chelator can be obtained, zinc alone is appropriate for your disease stage
4. What monitoring schedule makes sense during any transition

See medications-overview for a broader overview of how each treatment works, and missed-doses for guidance if you have already had an unplanned gap in treatment.

Summary

Scenario	Zinc alone appropriate?
New diagnosis, active liver disease	No — chelation required
Established neurological disease, symptomatic	No — chelation preferred
Long-term stable maintenance, normal liver function	Yes, with specialist agreement
Presymptomatic diagnosis (family screening)	Often yes, per guidelines
Bridge during temporary trientine supply gap	Possibly, with close monitoring

This article is for educational purposes. Treatment decisions — including any change from chelation to zinc or any medication importation — must be made in consultation with your Wilson disease specialist. Do not make unilateral changes to your treatment protocol.

References